Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma
Status:
Recruiting
Trial end date:
2025-10-01
Target enrollment:
Participant gender:
Summary
In this research study is looking to see how safe and effective belantamab mafodotin is in
relapsed or refractory plasmablastic lymphoma or ALK+ large B-cell lymphoma.
- This research study involves the study drug belantamab mafodotin.
- Belantamab mafodotin is an antibody-drug conjugate (ADC), which is the combination of an
antibody (a protein that binds to cells) and a drug. It works by using the antibody
portion to enter into the lymphoma cells, and then releasing the drug portion to kill
the lymphoma cells.